US EditionPublished • loading... • Updated
Acrobat Genomics Advances to Next Phase of AI-Powered Inhibitor Discovery Program
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Acrobat Genomics Advances to Next Phase of AI-Powered Inhibitor Discovery Program
SAN CARLOS, Calif.--(BUSINESS WIRE)--#AI--Today, Acrobat Genomics (“Acrobat”), a biotechnology company that teaches AI to design proteins using functional data measured directly in human cells, announced the successful completion of Phase I and commencement of expanded research within the Defense Advanced Research Projects Agency (DARPA) Rapid Inhibitor Discovery and Development pipeLine (RIDDL) program as a prime more... The post Acrobat Genomi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
